Serum uric acid can predict higher C-reactive protein levels in apparently healthy men;Ácido úrico sérico puede predecir mayores niveles de proteína C-reactiva en hombres adultos sanos

Nutricion Hospitalaria

Volumn 29, Issue 4, 2014, Pages 935-940

  de Carvalho Vidigal, Fernanda ^a   de Lima Rosado, Lina Enriqueta Frandsen Paez ^a   Rosado, Gilberto Paixão ^a   de Cassia Lanes Ribeiro, Rita ^a   do Carmo Castro Franceschini, Sylvia ^a  

^a FEDERAL UNIVERSITY OF VIÇOSA   (Brazil)

Author keywords

C reactive protein; Fibrinogen; Inflammation; Lipoproteins; Uric Acid

Indexed keywords

C REACTIVE PROTEIN; URIC ACID;

ADULT; BLOOD; CARDIOVASCULAR DISEASE; CROSS-SECTIONAL STUDY; HUMAN; MALE; METABOLISM; MIDDLE AGED; PREDICTIVE VALUE; PROCEDURES; RISK ASSESSMENT; YOUNG ADULT;

ADULT; C-REACTIVE PROTEIN; CARDIOVASCULAR DISEASES; CROSS-SECTIONAL STUDIES; HUMANS; MALE; MIDDLE AGED; PREDICTIVE VALUE OF TESTS; RISK ASSESSMENT; URIC ACID; YOUNG ADULT;

EID: 84897951982     PISSN: 02121611     EISSN: 16995198     Source Type: Journal    
DOI: 10.3305/nh.2014.29.4.7094     Document Type: Article

References (35)

1. Hak AE, Stehouwer CD, Bots ML, Polderman KH, Schalkwijk CG, Westendorp IC et al. Associations of C-reactive protein with measures of obesity, insulin resistance, and subclinical atheros - clerosis in healthy, middle-aged women. Arterioscler Thromb Vasc Biol 1999; 19 (8): 1986-91.
2. Braunwald E. Shattuck lecture - cardiovascular medicine at the turn of the millennium: triumphs, concerns, and opportunities. N Engl J Med 1997; 337: 1360-9.
3. Morais CAS, Oliveira SHV, Lima LM. Índices lipídicos tetravalente (LTI) e pentavalente (LPI) em indivíduos saudáveis. Arq Bras Cardiol 2013; 100 (4): 322-7.
4. Danesh J, Collins R, Appleby P, Peto R. Association of fibrinogen, C-reactive protein, albumin, or leukocyte count with coronary heart disease meta-analyses of prospective studies. JAMA 1998; 279 (18): 1477-82.
5. Koenig W, Sund M, Frohlich M, Fischer H-G, Lowel H, Doring A et al. C-reactive protein, a sensitive marker of inflammation, predicts future risk of coronary heart disease in initially healthy middle-aged men results from the MONICA (monitoring trends and determinants in cardiovascular disease) Augsburg cohort study, 1984 to 1992. Circulation 1999; 99: 237-42.
6. Das UN. Is obesity an inflammatory condition? Nutrition 2001; 17: 953-66.
7. Tarantino G, Colicchio P, Conca P, Finelli C, Di Minno MND, Tarantino M et al. Young adult obese subjects with and without insulin resistance: what is the role of chronic inflammation and how to weigh it non-invasively? J Inflamm 2009; 6 (6): 1-6.
8. Fujii C, Sakakibara H, Kondo T, Yatsuya H, Tamakoshi K, Toyoshima H. Plasma fibrinogen levels and cardiovascular risk factors in Japanese schoolchildren. J Epidemiol 2006; 16 (2): 64-70.
9. Shankar A, Wang JJ, Rochtchina E, Mitchell P. Positive association between plasma fibrinogen level and incident hypertension among men population-based cohort study. Hypertension 2006; 48: 1043-9.
10. Peixoto MRG, Monego ET, Jardim PCBV, Carvalho MM, Sousa ALL, Oliveira JS et al. Dieta e medicamentos no tratamento da hiperuricemia em pacientes hipertensos. Arq Bras Cardiol 2001; 76 (6): 463-7.
11. Gil-Campos M, Aguilera CM, Cañete R, Gil A. Uric acid is associated with features of insulin resistance syndrome in obese children at prepubertal stage. Nutr Hosp 2009; 24 (5): 607-13.
12. Lee J-M, Kim HC, Cho HM, Oh SM, Choi DP, Suh I. Association between serum uric acid level and metabolic syndrome. J Prev Med Public Health 2012; 45 (3).
13. Ioachimescu AG, Brennan DM, Hoar BM, Hazen SL, Hoogwerf BJ. Serum uric acid is an independent predictor of all-cause mortality in patients at high risk of cardiovascular disease a Preventive Cardiology Information System (PreCIS) Database Cohort Study. Arthritis Rheum 2008; 58 (2): 623-30.
14. World Health Organization. WHO Global Database on Body Mass Index (BMI): an Interactive Surveillance Tool for Monitoring Nutrition Transition. Public Health Nutr 2006; 9 (5): 658-60.
15. Sociedade Brasileira de Diabetes. Tratamento e acompanhamento do diabetes mellitus. Rio de Janeiro: Diagraphic; 2007.
16. Lee GR. Wintrobe: Hematologia Clínica. São Paulo: Manole; 1998.
17. Brasil AR, Norton RC, Rossetti MB, Leão E, Mendes RP. Creactive protein as an indicator of low intensity inflammation in children and adolescents with and without obesity. J Pediatr 2007; 83 (5): 477-80.
18. Petersson H, Daryani A, Riserus U. Sagittal abdominal diameter as a marker of inflammation and insulin resistance among immigrant women from the Middle East and native Swedish women: a cross-sectional study. Cardiovasc Diabetol 2007; 6: 10.
19. Organización Mundial de la Salud. El estado físico: uso e interpretación de la antropometría: informe de un Comitê de Expertos de la OMS. Ginebra: Oragización Mundial de la Salud; 1995.
20. World Health Organization. Obesity: preventing and managing the global epidemic. Report of a WHO consultation. Journal [serial on the Internet]. 2000 Date; 894.
21. Friedewald WT, Levy RI, Fredrickson DS. Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. Clin Chem 1972 Jun; 18 (6): 499-502.
22. Sociedade Brasileira de Cardiologia. III Diretrizes Brasileiras sobre Dislipidemias e Diretriz de Prevenção da Aterosclerose do Departamento de Aterosclerose da Sociedade Brasileira de Cardiologia. Arq Bras Cardiol 2001; (Supl. III): 48p.
23. Ridker PM. High-sensitivity C-reactive protein potential adjunct for global risk assessment in the primary prevention of cardiovascular disease. Circulation 2001; 103: 1813-8.
24. Hanley JA, McNeil BJ. A method of comparing the areas under receiver operating characteristic curves derived from the same cases. Radiology 1983 Sep; 148 (3): 839-43.
25. Vidigal FC, Rosado LEFPL, Rosado GP, Ribeiro RCL, Franceschini SCC, Priore SE et al. Predictive ability of the anthropometric and body composition indicators for detecting changes in inflammatory biomarkers. Nutr Hosp 2013; 28 (5): 1639-45.
26. Araújo F, Pereira AC, Latorre MDDO, Krieger JE, Mansur AJ. High-sensitivity C-reactive protein concentration in a healthy Brazilian population. Int J Cardiol 2004; 97: 433-8.
27. Imperatore G, Riccardi G, Iovine C, Rivellese AA, Vaccaro O. Plasma fibrinogen: a new factor of the metabolic syndrome -A population-based study. Diabetes Care 1998; 21 (4): 649-54.
28. Aronson D, Bartha P, Zinder O, Kerner A, Shitman E, Markiewicz W et al. Association between fasting glucose and C-reactive protein in middle-aged subjects. Diabet Med 2004; 21 (1): 39-44.
29. Gui M-h, Hong J, Lü A-k, Chen Y, Shen W-f, Li X-y et al. High sensitive C-reactive protein, adiponectin, and urine albumin excretion rate in Chinese coronary artery disease patients with different glucose tolerance status. Chin Med J 2008; 121 (24): 2509-16.
30. Forouhi NG, Sattar N, McKeigue PM. Relation of C-reactive protein to body fat distribution and features of the metabolic syndrome in Europeans and South Asians. Int J Obes 2001; 25: 1327-31.
31. Lemieux I, Pascot A, Prud'homme D, Alméras N, Bogaty P, Nadeau A et al. Elevated C-reactive protein another component of the atherothrombotic profile of abdominal obesity. Arterioscler Thromb Vasc Biol 2001; 21: 961-7.
32. Mohan V, Deepa R, Velmurugan K, Premalatha G. Association of C-reactive protein with body fat, diabetes and coronary artery disease in Asian Indians: The Chennai Urban Rural Epidemiology Study (CURES-6). Diabet Med 2005; 22: 863-70.
33. Nakamura H, Ito H, Egami Y, Kaji Y, Maruyama T, Koike G et al. Waist circumference is the main determinant of elevated Creactive protein in metabolic syndrome. Diabetes Res Clin Pract 2008; 79: 330-6.
34. Dupuy AM, Jaussent I, Lacroux A, Durant R, Cristol JP, Delcourt C et al. Waist circumference adds to the variance in plasma C-reactive protein levels in elderly patients with metabolic syndrome. Gerontology 2007; 53: 329-39.
35. Niizeki T, Takeishi Y, Kitahara T, Suzuki S, Sasaki T, Ishino M et al. Combination of conventional biomarkers for risk stratification in chronic heart failure. J Cardiol 2009; 53: 179-87.